Multiple innovations are enhancing diagnostic precision in oncology and genomics. AI-driven tools like PromoterAI identify pathogenic promoter mutations contributing to genetic diseases. The Association for Molecular Pathology issued standardized guidelines to harmonize homologous recombination deficiency (HRD) testing, a key cancer biomarker. Additionally, SandboxAQ released SAIR, the largest publicly available structural protein-ligand dataset, to facilitate AI applications in drug discovery. These advances collectively empower deeper molecular insights and accelerate targeted therapy development.